

INVESTIGATIVE REPORT

Skin Pain and Discomfort in Psoriasis: An Exploratory Study of Symptom Prevalence and Characteristics

Tone Marte LJOSAA¹, Tone RUSTOEN², Cato MØRK³, Audun STUBHAUG⁴, Christine MIASKOWSKI⁵, Steven M. PAUL⁵ and Astrid K. WAHL⁶

¹Department of Health Sciences, Buskerud University College, Drammen, ²Center for Patient Decision Making and Nursing Research, Departments of ³Dermatology and ⁴Anesthesiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Department of Psychological Nursing, University of California, San Francisco, USA, and ⁶Institute of Nursing and Health Sciences, University of Oslo, Oslo, Norway

Few studies have investigated subjective sensory skin symptoms in patients with psoriasis. The aim of this study was to investigate prevalence and characteristics of psoriasis-related skin pain and discomfort, and evaluate differences in demographic/clinical characteristics among patients with or without skin symptoms. A total of 139 patients was recruited for this exploratory, descriptive, cross-sectional study. Data were obtained through interviews and questionnaires. While 42.6% reported skin pain, 36.7% reported skin discomfort. Mean average symptom intensity score (0–10 numeric rating scale) was 4.4 for pain and 3.5 for discomfort. Unpleasant, surface, sensitive, itchy, and hot/burning were the most common symptom qualities. Sleep was the most severely affected function. No differences were found in demographic characteristics. However, larger proportions of patients with skin symptoms had more severe psoriasis ($p < 0.05$). In conclusion, pain and discomfort are more common and more severe in patients with psoriasis than previously estimated. *Key words: pain; discomfort; psoriasis; PASI.*

(Accepted September 18, 2009.)

Acta Derm Venereol 2010; 90: 39–45.

Tone Marte Ljosaa, Buskerud University College, Postboks 7053, NO-3007 Drammen, Norway. E-mail: tone.marte.ljosaa@hibu.no

While clinician-assessed physical signs have been the focus of most psoriasis research, there is increasing interest in the patients' experience of sensory symptoms. The progress and recognition of quality of life (QoL) and symptom management research (1), has led to the acceptance of patients' perception and self-report as the gold standard for studying symptoms. In fact, QoL studies (2–4) have shown that more than 90% of patients with psoriasis report physical skin symptoms.

Patients with psoriasis have been shown frequently to experience skin pain and skin discomfort (5, 6). Pain is a symptom defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage" (7). In a survey of skin disease in general practice 25% of patients with psoriasis reported pain (8). QoL studies

(9–13) found that patients with psoriasis reported bodily pain scores comparable to those of patients with heart disease and diabetes (14). In addition, psoriasis patient who were female, older (12), or had less education, chronic co-morbidities (13), more severe psoriasis, and psoriasis of longer duration (9, 10, 12) reported more pain. Of note, none of these studies (8–13, 15, 16) determined whether the pain was specific to psoriasis or other medical conditions. Only two studies (5, 17) found that 26–32% of patients with psoriasis reported that their skin hurt "often or all the time". Patients who were female, older, with less education or had more severe psoriasis, were more likely to report that their skin hurt.

Discomfort is a term commonly used in dermatology research and clinical practice to address sensory skin symptoms. However, no consensus definition of discomfort exists. Previous psoriasis studies applied discomfort either as an umbrella term for skin sensations (i.e. pain; itch; prickling; burning; tingling; stinging; soreness) and signs (i.e. scaling; suppuration) (13, 18–21), as a symptom synonymous to (20), or distinct from pain (22, 23), or as mental/social distress (18, 24). QoL studies (6, 25, 26) showed that at least 23% of patients reported discomfort from their psoriasis. Of note, these studies did not investigate discomfort in relation to demographic or clinical characteristics.

Symptom characteristics such as intensity, qualities, and interference with function are dimensions of the total pain experience (27). Only a limited number of studies reported pain or discomfort characteristics in patients with psoriasis. Research (21, 28) showed that patients with psoriasis reported pain or discomfort intensity scores in the mild to moderate range. In addition, QoL studies (6, 25, 26) showed that 23% of patients reported at least moderate discomfort and 8% reported extreme discomfort from their psoriasis. Sensitivity, burning/stinging, irritation, and itching in the skin were reported by 39–64% of patients with psoriasis (5, 17). While the studies referred to these sensations as distinct symptoms, pain research considers these sensations as symptom qualities (27). In terms of symptom interference, one study (13) showed that psoriasis-specific physical symptoms (i.e. itch, pain, burning, scaling) were related to poor physical function. Other studies

suggested that psoriasis-related discomfort interfered with normal work (6, 25) and sexual life (21).

For a number of reasons, the prevalence and specific characteristics of skin pain and skin discomfort in patients with psoriasis cannot be estimated from existing dermatology research. First, the large studies on skin pain prevalence included hospitalized, older patients with moderate to severe psoriasis. Secondly, several studies (6, 25, 26, 28) did not specify whether pain or discomfort was caused by psoriasis skin lesions or psoriasis arthritis. Thirdly, discomfort characteristics were described for only a rare psoriasis subtype (21). Finally, concepts such as symptoms, qualities, and signs were used inconsistently (5, 17) or collapsed into one overall psoriasis symptom entity (13).

Based on the paucity of research, the purposes of this exploratory study were: (i) to describe the prevalence of skin pain or skin discomfort reported by patients with psoriasis; (ii) to determine whether patients with psoriasis with skin pain, skin discomfort, or no skin pain/discomfort differed in any demographic and clinical characteristics; and (iii) to explore symptom characteristics (i.e. intensity, qualities, interference with function) of psoriasis-related skin pain or skin discomfort.

METHODS

Sample and setting

Patients were recruited prior to a consultation at the inpatient and outpatient dermatology units at a university hospital in Oslo, Norway, between January and September 2006. Patients were included if they: had a psoriasis diagnosis; were ≥ 18 years of age; were able to read and write Norwegian; had Caucasian skin type; and could differentiate skin pain from other bodily pain. Patients were excluded if, at the time of recruitment, they had: clinical signs of infection in psoriasis plaques; concomitant skin diseases that caused pain/discomfort; no clinically visible psoriasis; psychiatric diagnosis or cognitive impairment that prohibited them from completing the self-report questionnaires; or had started hospital treatment (e.g. phototherapy, baths).

One of five research nurses approached the patients in the outpatient or inpatient units and explained the study purpose and procedures. Patients who agreed to participate provided written informed consent. The study was recommended by the Regional Committee for Medical Research Ethics, region south, and approved by the Norwegian Data Inspectorate.

A total of 269 adult patients with psoriasis were registered for consultation in the dermatology units during the study period. Thirty-one patients (11.5%) were not invited to participate in the study due to scheduling conflicts. Of the 238 patients approached, 4 did not meet the inclusion criteria for the following reasons: uncertain psoriasis diagnosis ($n=1$), non-Caucasian skin type ($n=2$), and Norwegian illiteracy ($n=1$). In addition, 42 patients were excluded due to: concomitant skin diseases ($n=16$), ongoing hospital treatment ($n=14$), no psoriasis plaques at the time of recruitment ($n=5$), psychological problems ($n=4$), and cognitive impairment ($n=3$). Of a total of 192 eligible patients, 140 (72.9%) agreed to participate. After enrolment, one patient was excluded due to a change in diagnosis. The final sample therefore included 139 patients.

Study procedures

For each patient, a 30–40 min interview was conducted by one investigator (TML). Patients were screened for skin pain and

skin discomfort. Specific definitions of pain and discomfort were not provided, because this exploratory study aimed to investigate the patients' subjective experience of sensory skin symptoms without biasing their responses. During the interview, information was collected on demographic and clinical characteristics. A clinical evaluation of psoriasis severity was carried out and medical records were reviewed for disease and treatment information. Patients were shown how to complete the questionnaires (within 24 h) and return them in postage paid envelopes. The postal questionnaire response rate was 90.6%.

Instruments

Demographic characteristics. Information was collected on gender, age, ethnicity, marital status, living arrangements, education, and employment status.

Co-morbidity. Patients completed the Self-Administered Comorbidity Questionnaire (SCQ-18), which evaluated the number, severity, and functional impact of health problems (29). In this study, the SCQ contained 16 defined and 2 optional conditions (i.e. hypertension, diabetes, abdominal ulcer, headache, depression, osteoarthritis, rheumatoid arthritis, back/neck pain, cancer, musculoskeletal condition, and disease of the heart, lung, bowel, kidney, liver, blood). The total score range from 0 to 54. Higher scores indicate a more severe co-morbidity profile.

Prevalence of skin pain and skin discomfort. Two questions were used to screen patients into three skin symptom groups (i.e. pain, discomfort, no pain/discomfort). First, patients indicated, using a yes/no format, whether they had experienced any skin pain or skin discomfort during the past 24 h. Patients who responded yes indicated whether the sensation was pain or discomfort. Patients who reported both pain and discomfort ($n=3$) were categorized in the pain group.

Intensity of skin pain and skin discomfort. The Norwegian version of the Brief Pain Inventory (BPI) (30) was used to measure intensity of pain or discomfort on 0 (no symptom) to 10 (worst symptom imaginable) numeric rating scales (NRS). Four items address present, worst, least, and average pain or discomfort intensity over the past 24 h (30, 31). Suggested NRS cut-points for mild, moderate, and severe chronic non-malignant pain are 1–3, 4–6, and 7–10, respectively (32–35).

Qualities of skin pain and skin discomfort. The Pain Qualities Assessment Scale (PQAS) (36) was used to assess pain or discomfort qualities. For the purpose of this study, PQAS was translated from English to Norwegian using the Linguistic Validation method (37). This questionnaire includes 20 items that evaluate symptom intensity, quality, spatial characteristics, and temporal pattern over the past week. Each quality's severity is scored 0 (no/not [item]) to 10 (the most [item] sensation imaginable) on a NRS. These continuous variables were dichotomized into "not endorsed" (0) or "endorsed" (> 0) in order to determine the percentage of patients who endorsed particular symptom qualities.

Interference of skin pain and skin discomfort. The BPI (30) was used to evaluate interference of skin symptoms on a 0 (no interference) to 10 (worst interference imaginable) NRS. Seven items address symptom interference with daily activities, mood, walking ability, work, relations with other people, sleep, and enjoyment of life over the past 24 h (30, 31). Interference scores ≥ 4 indicate clinically significant interference with function in cancer patients (38, 39). The continuous variables of interference severity were dichotomized into "not endorsed" (0) or "endorsed" (> 0) in order to determine the percentage of patients who endorsed particular symptom interference items.

Clinical evaluation

Duration and severity of psoriasis. Psoriasis duration in years was obtained through patient interviews. Psoriasis severity was

determined using the Psoriasis Area and Severity Index (PASI). The PASI total score ranges from 0–72. Higher scores indicate greater psoriasis severity (40).

Overall psoriasis condition. Patients rated their overall condition of psoriasis as stable, improved, or exacerbated (41).

Medications and topical treatments for psoriasis. Information was collected on medication (i.e. non-prescription, prescription) and psoriasis treatment through patient interviews and from medical records. Treatments were collapsed into two groups (i.e. topical and/or phototherapy, or systemic alone or with topical- and/or phototherapy).

Statistical analysis

Data were analysed using the SPSS for Windows version 16.0 (SPSS, Inc., Chicago, US) and SPSS SamplePower 2.0. Descriptive statistics were generated on demographic, clinical, and symptom characteristics. Differences among the pain ($n=58$), discomfort ($n=51$), and no pain/discomfort ($n=30$) groups in categorical variables were examined with χ^2 and Fisher's exact test analyses. Differences among the three groups in continuous variables were examined with one-way analysis of variance (ANOVA) and Kruskal Wallis analyses. Nine pairwise contrasts were calculated to locate group differences in the categorical variable "overall psoriasis condition". The significance criterion for each of these contrasts was set at 0.006 (0.05/9). Three pairwise contrasts were calculated to locate group differences in the mean PASI score. The significance for each of these contrasts was set at 0.017 (0.05/3). For all other variables, a p -value of <0.05 was considered statistically significant. 95% confidence intervals (95% CI) were generated for the proportions of patients who reported skin pain or skin discomfort.

RESULTS

Prevalence

In this sample, 41.7% (95% CI, 33.8–50.0%) of patients reported skin pain and 36.7% (95% CI, 29.1–45.0%) of the patients reported skin discomfort.

Differences in demographic and clinical characteristics

The majority of the patients were women (56.8%), married (61.2%), and working (60.4%). Their mean age was 51.4 years (± 13.2 ; range 18–84 years). No differences were found among the three groups on any of the demographic characteristics (Table I).

The mean SCQ-18 score was 5.4 (± 4.3). Back/neck pain (38.8%), headache (28.8%), hypertension (24.5%), rheumatoid arthritis (22.3%), and depression (17.3%) were the most common co-morbidities. No differences were found among the three groups in terms of co-morbidity profile.

The mean PASI score was significantly higher in patients with pain (7.1 ± 5.8) and discomfort (5.4 ± 4.1) than patients with no pain/discomfort (2.7 ± 2.4) (all $p < 0.01$) (Table II). Higher percentages of patients in the pain and discomfort groups reported exacerbated psoriasis condition compared with those in the no pain/discomfort group ($p < 0.006$). Furthermore, a higher percentage of patients in the no pain/discomfort group reported improved psoriasis condition compared with those in the pain and discomfort groups ($p < 0.006$). No differences were found among the three groups in terms of mean duration of psoriasis, medication and topical treatment.

Symptom characteristics

Mean symptom intensity scores (0–10 NRS) ranged from 4.0 to 5.6 in the pain group, and from 2.7 to 3.7 in the discomfort group (Fig. 1).

Except for the quality "throbbing", no significant differences were found between the patients with pain

Table I. Differences in demographic characteristics among patients with pain, discomfort and no pain/discomfort

Characteristics	Pain $n=58$ (41.7%)	Discomfort $n=51$ (36.7%)	No pain/ discomfort $n=30$ (21.6%)	Statistics
Age (years), mean \pm SD	49.7 \pm 13.8	51.8 \pm 13.6	54.1 \pm 11.3	$F=1.136$ ($p=0.324$)
Gender, % (n)				
Male	39.7 (23)	37.3 (19)	60.0 (18)	$\chi^2 = 4.483$ ($p=0.106$)
Marital status, % (n)				
Unmarried	17.2 (10)	15.7 (8)	10.0 (3)	$p=0.531^a$
Married/cohabitant	53.4 (31)	66.7 (34)	66.7 (20)	
Divorced/widowed	29.3 (17)	17.6 (9)	23.3 (7)	
Living arrangement, % (n)				
Alone	27.6 (16)	25.5 (13)	16.7 (5)	$\chi^2 = 6.179$ ($p=0.186$)
Spouse	32.8 (19)	39.2 (20)	60.0 (18)	
Family/others	39.7 (23)	35.3 (18)	23.3 (7)	
Employment status, % (n)				
Employed	56.9 (33)	60.8 (31)	66.7 (20)	$\chi^2 = 0.794$ ($p=0.672$)
Unemployed	43.1 (25)	39.2 (20)	33.3 (10)	
Education, % (n)				
Primary school	12.1 (7)	15.7 (8)	23.3 (7)	$p=0.175^a$
Secondary school	44.8 (26)	47.1 (24)	23.3 (7)	
University ≤ 4 years	20.7 (12)	27.5 (14)	33.3 (10)	
University > 4 years	22.4 (13)	9.8 (5)	20.0 (6)	
Ethnicity, % (n)				
Norwegian	91.4 (53)	98.0 (50)	93.3 (28)	$p=0.329^a$
Other	8.6 (5)	2.0 (1)	6.7 (2)	

^aFisher's exact test. SD: standard deviation.

Table II. Differences in endorsed qualities and interference items between patients with pain, discomfort and no pain/discomfort

Characteristics	Pain (1) n = 58 (41.7%)	Discomfort (2) n = 51 (36.7%)	No pain/discomfort (3) n = 30 (21.6%)	Statistics
SCQ-18 (0–54), mean ± SD				
Co-morbidity score	5.6 ± 4.5	5.3 ± 4.1	5.2 ± 4.6	KW χ^2 = 0.385 (p = 0.825)
PASI (0–72), mean ± SD	7.1 ± 5.8	5.4 ± 4.1	2.7 ± 2.4	KW χ^2 = 20.648 (p < 0.0001) 1 and 2 > 3 ^a
Ps overall condition, % (n)				
Stable	22.4 (13)	25.5 (13)	43.3 (13)	χ^2 = 29.772 (p < 0.0001)
Improved	13.8 (8)	17.6 (9)	50.0 (15)	Not significant ^b
Exacerbated	63.8 (37)	56.9 (29)	6.7 (2)	1 and 2 < 3 ^b 1 and 2 > 3 ^b

^aStatistically significant pairwise contrast p < 0.017.

^bStatistically significant pairwise contrast p < 0.006.

KW: Kruskal Wallis test; MU: Mann-Whitney U test; PASI: Psoriasis Area and Severity Index; Ps: psoriasis; SCQ: Self-Administered Comorbidity Questionnaire; SD: standard deviation.

or discomfort in any of the symptom qualities they endorsed (Table III). In both groups, the most frequently reported qualities were unpleasant (100%), surface (99%), sensitive (96%), itchy (96%), hot/burning (93%), tender (84%), and tingling (79%). The mean severity scores (0–10 NRS) for these seven most common symptom qualities were significantly higher for the pain than the discomfort group (all p < 0.05). The severity scores ranged from 4.4 to 6.6 in patients with pain, and from 2.7 to 5.2 in patients with discomfort (Table IV).

Significantly higher percentages of patients with pain (88–94%) reported that their symptom interfered with mood, work, sleep, and relations with other people compared with patients with discomfort (54–77%) (all p < 0.05) (Table III). Mean severity scores (0–10 NRS) for the interference items ranged from 3.8 to 5.0 in patients with pain and from 1.9 to 2.7 in patients with discomfort (Table IV). Patients with pain reported signi-

ficantly higher severity scores on all interference items (all p ≤ 0.001), except from walking ability.

DISCUSSION

In this study, almost 80% of patients with psoriasis reported sensory skin symptoms. Patients with skin pain or skin discomfort had more severe psoriasis than those

Table III. Differences in endorsed qualities between patients with pain and discomfort

Symptom characteristics	Pain n = 58	Discomfort n = 51	Statistics ^b
Qualities ^a , % (n)			
Itchy	95.8 (46)	95.8 (46)	p = 1.000
Unpleasant	100.0 (49)	100.0 (48)	
Surface	98.0 (48)	100.0 (48)	p = 1.000
Sensitive	97.9 (47)	93.6 (44)	p = 0.362
Hot/burning	95.9 (47)	89.6 (43)	p = 0.268
Tender	91.5 (43)	76.6 (36)	p = 0.089
Tingling	87.5 (42)	70.8 (34)	p = 0.077
Aching	81.3 (39)	68.1 (32)	p = 0.162
Sharp	79.2 (38)	70.2 (33)	p = 0.352
Cramping/tight	63.8 (30)	52.1 (25)	p = 0.301
Throbbing	77.6 (38)	51.1 (24)	p = 0.010
Deep	70.2 (33)	68.8 (33)	p = 1.000
Heavy	64.6 (31)	45.8 (22)	p = 0.100
Radiating	63.0 (29)	68.8 (33)	p = 0.664
Shooting	57.4 (27)	41.7 (20)	p = 0.153
Dull	62.5 (30)	57.4 (27)	p = 0.678
Cold	44.7 (21)	33.3 (16)	p = 0.297
Numb	51.1 (24)	47.9 (23)	p = 0.838
Electric	34.0 (16)	35.4 (17)	p = 1.000
Interference with function ^a , % (n)			
Sleep	85.7 (42)	66.7 (32)	p = 0.033
Enjoyment of life	91.8 (45)	79.2 (38)	p = 0.090
Mood	93.9 (46)	77.1 (37)	p = 0.022
Work	91.7 (44)	66.7 (32)	p = 0.005
Daily activities	85.7 (42)	72.9 (35)	p = 0.139
Relationships with other people	87.8 (43)	54.2 (26)	p < 0.001
Walking ability	77.6 (38)	62.5 (30)	p = 0.124

^a“Endorsed” > 0 on an 11-point numeric rating scale (NRS).

^bFisher’s exact test.

Significant values are shown in bold.




Fig. 1. Present, worst, and average intensity (mean and standard deviation) of skin pain and skin discomfort over the past 24 h in patients with psoriasis. NRS: numeric rating scale.

Table IV. Differences in severity of qualities between patients with pain and discomfort

Symptom characteristics	Pain n=58 (53.2%)	Discomfort n=51 (46.8%)	Statistics
Severity of qualities (0–10 NRS), mean \pm SD			
Itchy	6.6 \pm 3.2	5.2 \pm 2.5	<i>t</i>=2.4, <i>p</i>=0.019
Unpleasant	6.0 \pm 2.3	4.4 \pm 2.3	<i>t</i>=3.3, <i>p</i>=0.001
Surface	6.0 \pm 2.5	4.2 \pm 2.3	<i>t</i>=3.8, <i>p</i><0.001
Sensitive	5.9 \pm 2.6	4.3 \pm 2.7	<i>t</i>=2.9, <i>p</i>=0.005
Hot/burning	5.6 \pm 2.8	3.7 \pm 2.5	<i>t</i>=3.6, <i>p</i><0.001
Tender	4.9 \pm 2.7	3.2 \pm 3.0	<i>t</i>=2.9, <i>p</i>=0.005
Tingling	4.4 \pm 3.0	2.7 \pm 2.7	<i>t</i>=3.1, <i>p</i>=0.003
Aching	3.9 \pm 3.1	2.2 \pm 2.3	<i>t</i>=3.1, <i>p</i>=0.003
Sharp	3.6 \pm 2.9	2.5 \pm 2.6	<i>t</i> =1.9, <i>p</i> =0.062
Cramping/tight	3.6 \pm 3.5	1.9 \pm 2.6	<i>t</i>=2.7, <i>p</i>=0.008
Throbbing	3.2 \pm 2.9	1.6 \pm 2.2	<i>t</i>=3.0, <i>p</i>=0.003
Deep	3.2 \pm 2.9	2.1 \pm 2.2	<i>t</i> =1.9, <i>p</i> =0.056
Heavy	3.2 \pm 3.2	1.6 \pm 2.2	<i>t</i>=2.8, <i>p</i>=0.006
Radiating	2.7 \pm 3.0	2.0 \pm 1.9	<i>t</i> =1.4, <i>p</i> =0.160
Shooting	2.5 \pm 3.1	1.3 \pm 2.1	<i>t</i>=2.1, <i>p</i>=0.037
Dull	2.2 \pm 2.4	1.9 \pm 2.2	<i>t</i> =0.6, <i>p</i> =0.558
Cold	2.0 \pm 2.8	1.0 \pm 1.9	<i>t</i> =1.9, <i>p</i> =0.058
Numb	1.8 \pm 2.5	1.8 \pm 2.6	<i>t</i> =0.0, <i>p</i> =0.975
Electrical	1.4 \pm 2.5	1.1 \pm 2.0	<i>t</i> =0.6, <i>p</i> =0.582
Severity of interference (0–10 NRS), mean \pm SD			
Sleep	5.0 \pm 3.1	2.6 \pm 2.6	<i>t</i>=4.1, <i>p</i><0.001
Enjoyment of life	4.9 \pm 3.2	2.7 \pm 2.6	<i>t</i>=3.9, <i>p</i><0.001
Mood	4.8 \pm 2.7	2.5 \pm 2.5	<i>t</i>=4.4, <i>p</i><0.001
Work	4.8 \pm 3.0	2.7 \pm 2.7	<i>t</i>=3.5, <i>p</i>=0.001
Daily activities	4.5 \pm 2.8	2.7 \pm 2.4	<i>t</i>=3.3, <i>p</i>=0.001
Relationships with other people	3.9 \pm 2.9	1.9 \pm 2.3	<i>t</i>=3.8, <i>p</i><0.001
Walking ability	3.8 \pm 3.0	2.7 \pm 3.2	<i>t</i> =1.8, <i>p</i> =0.072

Significant values are shown in bold.

NRS: numeric rating scale; SD: standard deviation.

with no skin pain/discomfort. Patients with skin pain reported mean pain intensity scores in the moderate range (32–35). Patients used common qualities such as unpleasant, surface, and sensitive to describe both pain and discomfort. In addition, sleep and enjoyment of life were the functions most severely affected by sensory skin symptoms.

The CI for symptom prevalence in the present study indicate that the population prevalence of skin pain probably ranges from 34% to 50% in patients who attend hospital care for psoriasis. Furthermore, the population prevalence of skin discomfort probably ranges from 29% to 45% in this patient population. The width ($\pm 8\%$) of these CI is relatively narrow. In fact, even the lower limits of these CI indicate higher symptom prevalence compared with estimates from previous research (5, 17, 25). This difference may be attributed to the fact that patients in the present study were asked directly about skin pain and discomfort rather than having the symptom included in a list of skin symptoms (42). In addition, the lower rates in other studies may be due to the exclusion of patients who reported milder symptom severity (25) or symptoms less frequent than “often” (5, 17).

In the present study, larger proportions of patients with pain or discomfort had more severe psoriasis, as well as exacerbation of skin disease, compared with patients with no pain/discomfort. These findings are supported by previous research (9, 10, 12). Of note, both skin lesions (e.g. a defective skin barrier, inflammation) and treatments are potential sources of pain and discomfort. However, in the present study patients did not specify whether the psoriasis itself or the treatments for psoriasis caused skin pain or discomfort.

In the present study, patients rated mean skin pain intensity scores in the moderate range (32–35) (Fig. 1). The ratings of average and worst skin pain were equivalent to pain intensity scores reported by patients with neuropathic pain conditions (32, 43). Cut-points are not established for discomfort intensity measured on 0–10 NRS. However, in the present study patients rated discomfort intensity at the lower end of the NRS (Fig. 1), which may be interpreted as mild symptom intensity. Of note, while all patients who reported discomfort were included in this study’s analyses, previous studies (6, 25, 26) included only patients who reported at least moderate discomfort. Methodological differences make it difficult to compare findings on discomfort intensity across studies.

Patients with skin pain and skin discomfort endorsed common symptom qualities (Table III). However, patients with pain reported higher severity scores for a majority of these qualities (Table IV). The most frequent and severe qualities reported by both groups may provide insight into a “set” of specific skin symptom qualities in patients with psoriasis. The “set” includes the affective quality of “unpleasant” and the spatial quality of “surface” rather than “deep”. In addition, the sensory qualities of “hot/burning”, “sensitive”, and “tender” are, from a clinical angle, consistent with psoriasis characteristics such as inflammation and skin trauma. “Sensitive”, “hot/burning”, and “itchy” are also common and severe qualities reported by patients with neuropathic pain conditions (44, 45). Of note, the type of skin pain (e.g. nociceptive, inflammatory, neuropathic) (46) in patients with psoriasis cannot be determined from this study. Further research that utilizes quantitative sensory testing and skin biopsies may provide such insight.

Larger proportions of patients with pain reported that their skin symptom interfered with function (Table III). These patients also reported more severe interference with function compared with patients with discomfort (Table IV). In fact, 5 of the 7 mean interference severity scores in the pain group were above 4, which suggests a clinically significant level of interference (38, 39). These findings are comparable to pain interference ratings reported by outpatients with cancer (47, 48) diabetic neuropathy (49), and herpes zoster (50). Interestingly, “sleep” and “enjoyment of life” were the interference items with the highest severity scores in the total sample. Previous research (51, 52) suggests

that sleep impairment may be a major problem for patients with psoriasis. Future studies need to examine in depth the association between skin symptoms and sleep disturbance. While previous QoL studies (13) show impaired function in patients with psoriasis, sensory skin symptoms' impact on function was not investigated. Of note, recent research (53) questions patients' ability to distinguish the cause of impaired function. Further studies are needed in order to establish the extent that skin sensory symptoms vs. other disease features have on interference with function.

Patients with pain, discomfort, or no pain/discomfort did not differ on any demographic characteristics. However, previous studies suggest that female gender is associated with pain in patients with psoriasis (2, 5, 12, 17). Recent research (54) showed that pain thresholds and pain tolerance levels were lower in women. Biological as well as psychological differences between the genders were suggested explanations for the higher prevalence and severity of pain found in women. The sample size of the present study may have been too small to detect gender differences.

Patients with or without skin symptoms did not differ in terms of age and co-morbidity profile, as opposed to findings from previous research (2, 5, 12). A possible explanation for the present study's findings may be that skin pain and discomfort from psoriasis was assessed specifically rather than pain and discomfort in general (10–15, 17–19, 28, 46). Therefore, the patients' report of psoriasis related skin pain and discomfort did not account for coexisting pain and discomfort from comorbidities associated with older age.

Some limitations of the present study are worth noting. The relatively small sample size may have precluded us from finding associations between demographic or clinical characteristics and pain and discomfort (2, 5, 17). Although patients were from several regions of Norway and had mild to severe psoriasis, findings may not be generalizable to general and private practice since the sample was recruited from one hospital dermatology unit. Finally, because of the methods used for quantifying symptom characteristics, a more comprehensive evaluation of the relation between pain and discomfort could not be performed.

In conclusion, findings from this study suggest that psoriasis-related skin pain and skin discomfort may be a larger problem than previously estimated.

ACKNOWLEDGEMENTS

The authors would like to thank the following persons and organizations for their assistance with various aspects of this study: Mark Jensen, Tore-Kr. Schjolberg, Randi Andenes, Alf-hild Dihle, Berit Valeberg, Karin Torvik, Liv I. Strand, Health and Rehabilitation, the Norwegian Research Council, and the US–Norway Fulbright Foundation.

The authors declare no conflict of interest.

REFERENCES

- Dodd M, Janson S, Facione N, Faucett J, Froelicher ES, Humphreys J, et al. Advancing the science of symptom management. *J Adv Nurs* 2001; 33: 668–676.
- Mork C, Wahl A, Moum T. The Norwegian version of the dermatology life quality index: a study of validity and reliability in psoriatics. *Acta Derm Venereol* 2002; 82: 347–351.
- Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. *Br J Dermatol* 2005; 152: 954–960.
- Shikier R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. *Health Qual Life Outcomes* 2003; 1: 53.
- Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. *Br J Dermatol* 2004; 151: 594–599.
- Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. *J Invest Dermatol* 2006; 126: 1480–1489.
- Merskey H, Bogduk N. Pain terms: a current list with definitions and notes on usage. In: Merskey H, Bogduk N, editor. *Classification of chronic pain*. Second edition. Seattle: IASP Press; 1994, p. 209–214.
- Verhoeven EW, Kraaijaat FW, van de Kerkhof PC, van Weel C, Duller P, van der Valk PG, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. *Br J Dermatol* 2007; 156: 1346–1349.
- Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. *Br J Dermatol* 2006; 154: 1161–1168.
- Shikier R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. *Health Qual Life Outcomes* 2006; 4: 71.
- Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. *Br J Dermatol* 1999; 141: 1067–1075.
- Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. *Br J Dermatol* 2006; 154: 844–849.
- Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. *J Am Acad Dermatol* 2000; 43: 803–808.
- Ware J. SF-36 Health survey manual and interpretation guide. Boston: New England Medical Center; 2000.
- Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. *Br J Dermatol* 2005; 153: 1192–1199.
- Ortonne JP, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. *BMC Dermatol* 2005; 5: 13.

17. Sampogna F, Tabolli S, Mastroeni S, Di Pietro C, Fortes C, Abeni D. Quality of life impairment and psychological distress in elderly patients with psoriasis. *Dermatology* 2007; 215: 341–347.
18. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. *J Am Acad Dermatol* 2003; 49: 271–275.
19. Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. *J Eur Acad Dermatol Venereol* 2007; 21: 466–472.
20. Robinson DJ, Collins P, Stringer MR, Vernon DI, Stables GI, Brown SB, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. *Acta Derm Venereol* 1999; 79: 451–455.
21. Zamirska A, Reich A, Berny-Moreno J, Salomon J, Szepletowski JC. Vulvar pruritus and burning sensation in women with psoriasis. *Acta Derm Venereol* 2008; 88: 132–135.
22. Chan MK, Chong LY. A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong. *J Am Podiatr Med Assoc* 2002; 92: 450–456.
23. Haneke E. Achilles foot-screening project: background, objectives and design. *J Eur Acad Dermatol Venereol* 1999; 12: 6–9.
24. Leary MR, Rapp SR, Herbst KC, Exum ML, Feldman SR. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. *Health Psychol* 1998; 17: 530–536.
25. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. *J Am Acad Dermatol* 1997; 36: 388–394.
26. Nijsten T, Sampogna F, Stern RS, Abeni D. The reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients. *Dermatology* 2007; 215: 348–351.
27. Melzack R, Katz J. Pain assessment in adult patients. In: McMahon SB, Koltzenburg M, editor. *Wall and Melzack's textbook of pain*. 5th edn. Philadelphia: Elsevier/Churchill Livingstone,; 2006, p. 291–292.
28. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. *J Dermatolog Treat* 2007; 18: 341–350.
29. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. *Arthritis Rheum* 2003; 49: 156–163.
30. Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. *J Pain Symptom Manage* 2002; 24: 517–525.
31. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singapore* 1994; 23: 129–138.
32. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. *Pain* 2005; 115: 29–36.
33. Jensen MP, Smith DG, Ehde DM, Robinsin LR. Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate, and severe pain. *Pain* 2001; 91: 317–322.
34. Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. *J Gen Intern Med* 2007; 22: 1453–1458.
35. Hanley MA, Masedo A, Jensen MP, Cardenas D, Turner JA. Pain interference in persons with spinal cord injury: classification of mild, moderate, and severe pain. *J Pain* 2006; 7: 129–133.
36. Jensen MP, Gammaitoni AR, Olaleye DO, Oleka N, Nalamachu SR, Galer BS. The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome. *J Pain* 2006; 7: 823–832.
37. Acquadro C, Conway K, Girourdet C, Mear I. *Linguistic Validation Manual for Patient-Reported Outcomes (PRO) Instruments*. Lyon: Mapi Research Institute; 2004.
38. Paul SM, Zelman DC, Smith M, Miaskowski C. Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. *Pain* 2005; 113: 37–44.
39. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. *Pain* 1995; 61: 277–284.
40. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. *Dermatologica* 1978; 157: 238–244.
41. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. *Arch Dermatol* 1997; 133: 1433–1440.
42. Dihle A, Bjolseth G, Helseth S. The gap between saying and doing in postoperative pain management. *J Clin Nurs* 2006; 15: 469–479.
43. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. *Clin J Pain* 2008; 24: 51–55.
44. Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. *J Pain* 2007; 8: 118–126.
45. Oaklander AL. Mechanisms of pain and itch caused by herpes zoster (shingles). *J Pain* 2008; 9: 10–18.
46. Devor M. Response of nerves to injury in relation to neuropathic pain. In: McMahon SB Koltzenburg M, editor. *Wall and Melzack's textbook of pain*. 5th edn. Philadelphia: Elsevier/Churchill Livingstone; 2006, p. 905.
47. Valeberg BT, Rustoen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. *Eur J Pain* 2008; 12: 582–590.
48. Edrington JM, Paul S, Dodd M, West C, Facione N, Tripathy D, et al. No evidence for sex differences in the severity and treatment of cancer pain. *J Pain Symptom Manage* 2004; 28: 225–232.
49. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. *Diabetes Res Clin Pract* 2000; 47: 123–128.
50. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. *Clin J Pain* 2007; 23: 490–496.
51. de Korte J, Sprangers MA, Mommers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. *J Investig Dermatol Symp Proc* 2004; 9: 140–147.
52. Duffin KC, Wong B, Horn EJ, Krueger GG. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. *J Am Acad Dermatol* 2009; 60: 604–608.
53. Holen JC, Lydersen S, Klepstad P, Loge JH, Kaasa S. The Brief Pain Inventory: pain's interference with functions is different in cancer pain compared with noncancer chronic pain. *Clin J Pain* 2008; 24: 219–225.
54. Dawson A, List T. Comparison of pain thresholds and pain tolerance levels between Middle Easterners and Swedes and between genders. *J Oral Rehabil* 2009; 36: 271–278.